These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 22167408)
21. [Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System Metastases from Non-small Cell Lung Cancer]. Jin Y; Xin T Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):496-500. PubMed ID: 27561797 [TBL] [Abstract][Full Text] [Related]
22. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Zimmermann S; Dziadziuszko R; Peters S Cancer Treat Rev; 2014 Jul; 40(6):716-22. PubMed ID: 24759599 [TBL] [Abstract][Full Text] [Related]
23. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Popat S; Hughes S; Papadopoulos P; Wilkins A; Moore S; Priest K; Meehan L; Norton A; O'Brien M Lung Cancer; 2007 Apr; 56(1):135-7. PubMed ID: 17157952 [TBL] [Abstract][Full Text] [Related]
24. [Systemic treatment of brain metastases from lung cancer]. Barlesi F; Spano JP; Cortot AB; Carpentier AF; Robinet G; Besse B Cancer Radiother; 2015 Feb; 19(1):43-7. PubMed ID: 25656857 [TBL] [Abstract][Full Text] [Related]
25. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Togashi Y; Masago K; Fukudo M; Tsuchido Y; Okuda C; Kim YH; Ikemi Y; Sakamori Y; Mio T; Katsura T; Mishima M Cancer Chemother Pharmacol; 2011 Oct; 68(4):1089-92. PubMed ID: 21681573 [TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082 [TBL] [Abstract][Full Text] [Related]
28. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Khandekar MJ; Piotrowska Z; Willers H; Sequist LV Oncologist; 2018 Sep; 23(9):1054-1062. PubMed ID: 29703765 [TBL] [Abstract][Full Text] [Related]
29. Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer. Ceresoli GL Curr Cancer Drug Targets; 2012 Mar; 12(3):237-46. PubMed ID: 22229252 [TBL] [Abstract][Full Text] [Related]
30. Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies. Tsakonas G; De Petris L; Ekman S Cancer Treat Rev; 2017 Mar; 54():122-131. PubMed ID: 28254730 [TBL] [Abstract][Full Text] [Related]
31. [I. Management of Brain Metastasis in Patients with Lung Cancer]. Kubota K Gan To Kagaku Ryoho; 2017 Jun; 44(6):475-478. PubMed ID: 28698437 [No Abstract] [Full Text] [Related]
32. Brain metastasis: opportunity for drug development? Preusser M; Berghoff AS; Schadendorf D; Lin NU; Stupp R Curr Opin Neurol; 2012 Dec; 25(6):786-94. PubMed ID: 23108247 [TBL] [Abstract][Full Text] [Related]
33. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Liao BC; Lin CC; Yang JC Expert Opin Pharmacother; 2018 Jun; 19(8):851-864. PubMed ID: 29726292 [TBL] [Abstract][Full Text] [Related]
34. Systemic Treatment of Brain Metastases. Waqar SN; Morgensztern D; Govindan R Hematol Oncol Clin North Am; 2017 Feb; 31(1):157-176. PubMed ID: 27912831 [TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases. Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Masago K; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y Anticancer Res; 2015 Feb; 35(2):1025-31. PubMed ID: 25667490 [TBL] [Abstract][Full Text] [Related]
37. Molecular subtyping of brain metastases and implications for therapy. Renfrow JJ; Lesser GJ Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440 [TBL] [Abstract][Full Text] [Related]
38. Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer? Chamberlain MC J Clin Oncol; 2013 Sep; 31(25):3164-5. PubMed ID: 23897966 [No Abstract] [Full Text] [Related]
39. Role of chemotherapy on brain metastasis. Lee SH Prog Neurol Surg; 2012; 25():110-4. PubMed ID: 22236672 [TBL] [Abstract][Full Text] [Related]
40. Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer. Huang YJ; Liu SF; Wang CJ; Huang MY Lung Cancer; 2008 Mar; 59(3):407-10. PubMed ID: 17804114 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]